These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 8744561)

  • 41. Safety and Immunogenicity of a Tetravalent Dengue Vaccine Candidate in Healthy Children and Adults in Dengue-Endemic Regions: A Randomized, Placebo-Controlled Phase 2 Study.
    Sirivichayakul C; Barranco-Santana EA; Esquilin-Rivera I; Oh HM; Raanan M; Sariol CA; Shek LP; Simasathien S; Smith MK; Velez ID; Wallace D; Gordon GS; Stinchcomb DT
    J Infect Dis; 2016 May; 213(10):1562-72. PubMed ID: 26704612
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Chimeric dengue 2 PDK-53/West Nile NY99 viruses retain the phenotypic attenuation markers of the candidate PDK-53 vaccine virus and protect mice against lethal challenge with West Nile virus.
    Huang CY; Silengo SJ; Whiteman MC; Kinney RM
    J Virol; 2005 Jun; 79(12):7300-10. PubMed ID: 15919884
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The association of enhancing antibodies with seroconversion in humans receiving a dengue-2 live-virus vaccine.
    Eckels KH; Kliks SC; Dubois DR; Wahl LM; Bancroft WH
    J Immunol; 1985 Dec; 135(6):4201-3. PubMed ID: 4067313
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dengue 2 PDK-53 virus as a chimeric carrier for tetravalent dengue vaccine development.
    Huang CY; Butrapet S; Tsuchiya KR; Bhamarapravati N; Gubler DJ; Kinney RM
    J Virol; 2003 Nov; 77(21):11436-47. PubMed ID: 14557629
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety and Immunogenicity of a Tetravalent Dengue DNA Vaccine Administered with a Cationic Lipid-Based Adjuvant in a Phase 1 Clinical Trial.
    Danko JR; Kochel T; Teneza-Mora N; Luke TC; Raviprakash K; Sun P; Simmons M; Moon JE; De La Barrera R; Martinez LJ; Thomas SJ; Kenney RT; Smith L; Porter KR
    Am J Trop Med Hyg; 2018 Mar; 98(3):849-856. PubMed ID: 29363446
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. IV. Characterization of a vaccine candidate in fetal rhesus lung cells.
    Halstead SB; Eckels KH; Putvatana R; Larsen LK; Marchette NJ
    Am J Trop Med Hyg; 1984 Jul; 33(4):679-83. PubMed ID: 6476215
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Immunogenicity and safety of a tetravalent dengue vaccine in healthy adults in India: A randomized, observer-blind, placebo-controlled phase II trial.
    Dubey AP; Agarkhedkar S; Chhatwal J; Narayan A; Ganguly S; Wartel TA; Bouckenooghe A; Menezes J
    Hum Vaccin Immunother; 2016; 12(2):512-8. PubMed ID: 26291554
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dengue-4 vaccine: neurovirulence, viraemia and immune responses in rhesus and cynomolgus monkeys.
    Angsubhakorn S; Yoksan S; Bhamarapravati N; Moe JB; Marchette NJ; Pradermwong A; Sahaphong S
    Trans R Soc Trop Med Hyg; 1988; 82(5):746-9. PubMed ID: 3252595
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Safety and immunogenicity of different doses and schedules of a live attenuated tetravalent dengue vaccine (TDV) in healthy adults: A Phase 1b randomized study.
    Rupp R; Luckasen GJ; Kirstein JL; Osorio JE; Santangelo JD; Raanan M; Smith MK; Wallace D; Gordon GS; Stinchcomb DT
    Vaccine; 2015 Nov; 33(46):6351-9. PubMed ID: 26384447
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A recombinant, chimeric tetravalent dengue vaccine candidate based on a dengue virus serotype 2 backbone.
    Osorio JE; Wallace D; Stinchcomb DT
    Expert Rev Vaccines; 2016; 15(4):497-508. PubMed ID: 26635182
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Limited potential for transmission of live dengue virus vaccine candidates by Aedes aegypti and Aedes albopictus.
    Sardelis MR; Edelman R; Klein TA; Innis BL; Putnak JR; Jones JW; Turell MJ
    Am J Trop Med Hyg; 2000 Jun; 62(6):698-701. PubMed ID: 11304057
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys.
    Blaney JE; Matro JM; Murphy BR; Whitehead SS
    J Virol; 2005 May; 79(9):5516-28. PubMed ID: 15827166
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Construction of infectious cDNA clones for dengue 2 virus: strain 16681 and its attenuated vaccine derivative, strain PDK-53.
    Kinney RM; Butrapet S; Chang GJ; Tsuchiya KR; Roehrig JT; Bhamarapravati N; Gubler DJ
    Virology; 1997 Apr; 230(2):300-8. PubMed ID: 9143286
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Safety and immunogenicity of one versus two doses of Takeda's tetravalent dengue vaccine in children in Asia and Latin America: interim results from a phase 2, randomised, placebo-controlled study.
    Sáez-Llorens X; Tricou V; Yu D; Rivera L; Tuboi S; Garbes P; Borkowski A; Wallace D
    Lancet Infect Dis; 2017 Jun; 17(6):615-625. PubMed ID: 28365225
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity.
    Poo J; Galan F; Forrat R; Zambrano B; Lang J; Dayan G
    Pediatr Infect Dis J; 2011 Jan; 30(1):e9-17. PubMed ID: 21042231
    [TBL] [Abstract][Full Text] [Related]  

  • 56. rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.
    Durbin AP; McArthur JH; Marron JA; Blaney JE; Thumar B; Wanionek K; Murphy BR; Whitehead SS
    Hum Vaccin; 2006; 2(6):255-60. PubMed ID: 17106267
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A phase 1 study of safety and immunogenicity following intradermal administration of a tetravalent dengue vaccine candidate.
    Jackson LA; Rupp R; Papadimitriou A; Wallace D; Raanan M; Moss KJ
    Vaccine; 2018 Jun; 36(27):3976-3983. PubMed ID: 29789238
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunogenicity of the CYD tetravalent dengue vaccine using an accelerated schedule: randomised phase II study in US adults.
    Kirstein J; Douglas W; Thakur M; Boaz M; Papa T; Skipetrova A; Plennevaux E
    BMC Infect Dis; 2018 Sep; 18(1):475. PubMed ID: 30241510
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Current status of dengue vaccines and prospects for the future.
    Bancroft WH
    P R Health Sci J; 1987 Apr; 6(1):23-6. PubMed ID: 3615797
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Dengue virus specific T cell responses to live attenuated monovalent dengue-2 and tetravalent dengue vaccines.
    Rabablert J; Dharakul T; Yoksan S; Bhamarapravati N
    Asian Pac J Allergy Immunol; 2000 Dec; 18(4):227-35. PubMed ID: 11316044
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.